Macropore Inc. IR-Pages
MacroPore Biosurgery to Webcast 2003 Year End Results on March 30, 2004
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
MacroPore Biosurgery to Webcast 2003 Fourth Quarter and Year End Results on
March 30, 2004
San Diego, CA, March 24, 2004 – Macropore Biosurgery, Inc. (Frankfurt: XMP)
(MacroPore) today announced it will release its 2003 fourth quarter and year end
results on Tuesday, March 30, 2004 at approximately 4:00 p.m. Central European
Summer Time (CEST) or 10:00 a.m. Eastern Standard Time (EST). The announcement
will be followed by a conference call at 4:30 p.m. (CEST) or 10:30 a.m. (EST)
hosted by Christopher J. Calhoun, President and Chief Executive Officer, and
Marc H. Hedrick, MD, Chief Scientific Officer.
The conference call will be webcast live and may be accessed on the Investor
Relations section of the Company’s website at http://www.macropore.com. An
archived version of the webcast will be available at the same website 60 Minutes
after the call. A telephone replay will be available for 24 hours. To access
the replay, please call +49 / 69 / 58 99 90 568 (PIN: 132415#).
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) (MacroPore) is focused on the discovery
and development of regenerative medicine technologies. We are committed to
improving the practice of medicine by creating innovative products that address
spine and orthopedic bone repair and cardiovascular tissue repair. Our surgical
implants, which represent one of the latest advancements in spine and orthopedic
medicine, are manufactured by us and distributed exclusively through Medtronic
Sofamor Danek. We are conducting research and development for an autologous,
homologous-use, cell-based technology for the regeneration and repair of damaged
tissues throughout the body. We are currently targeting the repair of
cardiovascular tissues that are damaged after a myocardial infarction. For
further information please visit our web site http://www.macropore.com.
Contact:
MacroPore Biosurgery, Inc.
Tom Baker
Media & U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
MacroPore Biosurgery, Inc.
Stefanie Bacher
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
edicto GmbH
Axel Mühlhaus/Sönke Knop
European Investor &
Press Agency
Tel.: +49 (0) 60 84 94 85-90
kontakt@edicto.de
end of message, (c)DGAP 24.03.2004
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
240800 Mär 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found